(Q28246190)

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin during primary PCI in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin started during emergency transport for primary PCI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Early versus delayed, provisional eptifibatide in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abcixi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin v

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Platelet inhibition with cangrelor during PCI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Interventio

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961216-2

7 January 2021

10.1016/S0140-6736(14)61216-2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25131979

1 reference

Consolidated OpenCitations Corpus – April 2017